{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:20:14Z","timestamp":1794540014595,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Services Inc., no grant number"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In ASCEMBL, an open-label, randomized Phase 3 study, asciminib demonstrated superior efficacy and better safety profile compared with bosutinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with \u22652 tyrosine kinase inhibitors. Health-related quality of life (HRQOL) reported by patients is key to understanding the benefit and impact of treatment on patients\u2019 lives, and is becoming increasingly important as the life expectancy of CML-CP patients increases and patients require long-term treatment. In ASCEMBL, patients completed questionnaires to assess CML symptoms and interference with daily life (M.D. Anderson Symptom Inventory \u2013 CML [MDASI-CML]), general HRQOL (five-level EQ-5D [EQ-5D-5L], Patient Global Impression of Change \u2013 CML [PGIC-CML]), and impact of CML on working life and activity (Work Productivity and Activity Impairment questionnaire \u2013 CML [WPAI-CML]). Patients\u2019 CML symptoms and HRQOL remained stable during 48 weeks of treatment with asciminib, with a general trend for decreased CML symptom severity, particularly for fatigue, and improvement in HRQOL. A clinically meaningful increase in diarrhea severity was observed in patients treated with bosutinib compared to asciminib. These data provide better understanding of the patient perspective and treatment impact on HRQOL in a later-line setting, where little information has been published to date.<\/jats:p>","DOI":"10.1038\/s41375-023-01888-y","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T08:02:45Z","timestamp":1681718565000},"page":"1060-1067","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Health-related quality of life of patients with resistant\/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5379-7461","authenticated-orcid":false,"given":"Delphine","family":"R\u00e9a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Boquimpani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2251-4032","authenticated-orcid":false,"given":"Michael J.","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-0739","authenticated-orcid":false,"given":"Yosuke","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Allepuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikalp Kumar","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"D\u2019Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9499-8443","authenticated-orcid":false,"given":"Rachael","family":"Lawrance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarunas","family":"Narbutas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giora","family":"Sharf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0626-0834","authenticated-orcid":false,"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"1888_CR1","unstructured":"American Cancer Society. Key Statistics for Chronic Myeloid Leukemia 01\/12\/2022 [03\/01\/2022]. https:\/\/www.cancer.org\/cancer\/chronic-myeloid-leukemia\/about\/statistics.html."},{"key":"1888_CR2","first-page":"935","volume":"8","author":"MH Cohen","year":"2002","unstructured":"Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8:935\u201342.","journal-title":"Clin Cancer Res"},{"key":"1888_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1182\/asheducation-2016.1.164","volume":"2016","author":"J Cortes","year":"2016","unstructured":"Cortes J, Kantarjian H. Chronic myeloid leukemia: sequencing of TKI therapies. Hematol Am Soc Hematol Educ Program. 2016;2016:164\u20139.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1888_CR4","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"1888_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","volume":"14","author":"J Cortes","year":"2021","unstructured":"Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021;14:44.","journal-title":"J Hematol Oncol"},{"key":"1888_CR6","first-page":"1","volume":"11","author":"MJ Mauro","year":"2013","unstructured":"Mauro MJ, Talpaz M, Radich JP. Sequential therapy in chronic myelogenous leukemia: where do emerging therapies fit within current treatment regimens? Clin Adv Hematol Oncol. 2013;11:1\u201315.","journal-title":"Clin Adv Hematol Oncol."},{"key":"1888_CR7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/asheducation-2016.1.170","volume":"2016","author":"F Efficace","year":"2016","unstructured":"Efficace F, Cannella L. The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. Hematol Am Soc Hematol Educ Program. 2016;2016:170\u20139.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1888_CR8","doi-asserted-by":"crossref","unstructured":"Negi H, Agrawal R, Vieira J, Ryan J, Thakur D, Viana R. PCN231: Humanistic and economic burden in patients with chronic myeloid leukemia \u2013 a review of the literature. Value in Health. 2021;24:S63.","DOI":"10.1016\/j.jval.2021.04.321"},{"key":"1888_CR9","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 2017;543:733\u20137.","journal-title":"Nature"},{"key":"1888_CR10","doi-asserted-by":"publisher","first-page":"106458","DOI":"10.1016\/j.leukres.2020.106458","volume":"98","author":"PW Manley","year":"2020","unstructured":"Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98:106458.","journal-title":"Leuk Res"},{"key":"1888_CR11","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D R\u00e9a","year":"2021","unstructured":"R\u00e9a D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 2021;138:2031\u201341.","journal-title":"Blood"},{"key":"1888_CR12","unstructured":"US Food and Drug Administration. SCEMBLIX\u00ae (asciminib) tablets, for oral use 10\/2021 [05\/23\/2022]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215358s000Orig1lbl.pdf."},{"key":"1888_CR13","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Boquimpani C, Rea D, Minami Y, Lomaia E, Voloshin S, et al. Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with \u22652 Tyrosine Kinase Inhibitors (TKIs). Blood. 2020;136:LBA-4-LBA-.","DOI":"10.1182\/blood-2020-143816"},{"key":"1888_CR14","doi-asserted-by":"crossref","unstructured":"Mauro MJ, Minami Y, Rea D, Hochhaus A, Lomaia E, Voloshin S, et al. Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after \u22652 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks. Blood. 2021;138(Supplement 1):310.","DOI":"10.1182\/blood-2021-152561"},{"key":"1888_CR15","doi-asserted-by":"crossref","unstructured":"Mauro MJ, Boquimpani C, R\u00e9a D, Hochhaus A, Maheshwari VK, Allepuz A, et al. CML-417: ASCEMBL Phase 3 Health-Related Quality of Life (HRQL) Comparison of Asciminib and Bosutinib for Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated with 2 or More Tyrosine Kinase Inhibitors (TKI). Clinical Lymphoma Myeloma and Leukemia. 2021;21:S336.","DOI":"10.1016\/S2152-2650(21)01785-7"},{"key":"1888_CR16","unstructured":"Cleeland C The M. D. Anderson Symptom Inventory User Guide Version 1 2016 [1\/3\/2019]. https:\/\/www.mdanderson.org\/documents\/Departments-and-Divisions\/Symptom-Research\/MDASI_userguide.pdf."},{"key":"1888_CR17","doi-asserted-by":"crossref","unstructured":"Williams LA, Garcia-Gonzalez A, Ault PS, Mendoza TR, Cleeland CS, Mobley GM, et al. A new symptom measure in chronic myeloid leukemia [Abstract]. American Society of Clinical Oncology 47th Annual Meeting; June 3\u20137, 2011; Chicago, IL: Journal of Clinical Oncology; 2011. p. e19545.","DOI":"10.1200\/jco.2011.29.15_suppl.e19545"},{"key":"1888_CR18","doi-asserted-by":"crossref","unstructured":"Williams LA, Cortes JE, Ault PS, Garcia-Gonzalez A, Williams JL, Cleeland CS. Including Patient Input In Patient-Reported Outcome Instrument Development: Examples From the MDASI-CML. Blood. 2010;116:2573.","DOI":"10.1182\/blood.V116.21.2573.2573"},{"key":"1888_CR19","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727\u201336.","journal-title":"Qual Life Res"},{"key":"1888_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353\u201365.","journal-title":"Pharmacoeconomics"},{"key":"1888_CR21","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. IQWiG General Methods: Version 6.0 of 5 November 2020 2020. https:\/\/www.iqwig.de\/methoden\/general-methods_version-6-0.pdf."},{"key":"1888_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-5-70","volume":"5","author":"AS Pickard","year":"2007","unstructured":"Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.","journal-title":"Health Qual Life Outcomes"},{"key":"1888_CR23","doi-asserted-by":"crossref","unstructured":"Fairclough DL. Design and analysis of quality of life studies in clinical trials, 2nd ed. London: CRC Press; 2010.","DOI":"10.1201\/9781420061185"},{"key":"1888_CR24","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","volume":"41","author":"GR Norman","year":"2003","unstructured":"Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582\u201392.","journal-title":"Med Care"},{"key":"1888_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10198-018-0955-5","volume":"20","author":"MF Janssen","year":"2019","unstructured":"Janssen MF, Szende A, Cabases J, Ramos-Go\u00f1i JM, Vilagut G, K\u00f6nig HH. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. 2019;20:205\u201316.","journal-title":"Eur J Health Econ"},{"key":"1888_CR26","first-page":"734","volume":"102","author":"J Garry","year":"2017","unstructured":"Garry J, Murphy P, Quinn J, Thornton P, Sargent J, McCloy M, et al. A multicentre audit of symptoms and quality of life in Irish CML patients on tyrosine kinase inhibitors. Haematologica 2017;102:734\u20135.","journal-title":"Haematologica"},{"key":"1888_CR27","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s11136-021-02794-5","volume":"30","author":"S Foulon","year":"2021","unstructured":"Foulon S, Cony-Makhoul P, Guerci-Bresler A, Daban M, Kapso R, Tubert-Bitter P, et al. Health state utility and quality of life measures in patients with chronic myeloid leukemia in France. Qual Life Res. 2021;30:2021\u201332.","journal-title":"Qual Life Res"},{"key":"1888_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00475-7","volume":"11","author":"AE E\u015fkazan","year":"2021","unstructured":"E\u015fkazan AE. Asciminib in chronic myeloid leukemia: many questions still remain to be answered. Blood Cancer J. 2021;11:81.","journal-title":"Blood Cancer J"},{"key":"1888_CR29","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872\u201384.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01888-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01888-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01888-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T10:58:04Z","timestamp":1683716284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01888-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1888"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-01888-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"assertion":[{"value":"23 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was funded by Novartis Services Inc. DR: honoraria from Novartis (including medical writing support for this current publication), Incyte, and Pfizer. CB: Speakers Bureau for Novartis, Janssen, and Pint Pharma; Board of Directors or advisory committees for Novartis and Janssen. MJM: personal fees from Bristol Myers Squibb, Takeda, and Pfizer. YM: honoraria from Novartis, BMS, Pfizer, and Astellas. AA, DD\u2019A, and YW: employees of Novartis and holders of Novartis stock\/shares. VKM: employee of Novartis at the time of conduct of this study. RL: employee of Adelphi Values, a consulting firm that received funding from Novartis to produce this work. SN and GS: Novartis advisory board and steering committee members. AH: research funding from Novartis, Bristol Myers Squibb, Pfizer, and Incyte.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}